Compare NMZ & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMZ | ERAS |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | NMZ | ERAS |
|---|---|---|
| Price | $10.67 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.78 |
| AVG Volume (30 Days) | 453.1K | ★ 3.7M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | ★ 16.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.36 | $1.01 |
| 52 Week High | $11.34 | $14.17 |
| Indicator | NMZ | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 65.24 | 76.07 |
| Support Level | $10.49 | $1.27 |
| Resistance Level | $10.66 | N/A |
| Average True Range (ATR) | 0.06 | 0.73 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 66.67 | 78.30 |
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.